Robert Radinsky
Impact in
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Research top 0.5%
- Cancer, Hypoxia, and Metabolism
- Cancer Genomics and Diagnostics
Papers in
- Oncology 67
- Cancer Cells and Metastasis 16
- HER2/EGFR in Cancer Research 15
- Colorectal Cancer Treatments and Studies 15
- Cancer-related Molecular Pathways 12
-
- Angiogenesis and VEGF in Cancer 14
- Co-authors
- Daniel J. Freeman (17 shared papers)Todd Juan (6 shared papers)Rafael G. Amado (5 shared papers)Eric Van Cutsem (3 shared papers)Marc Peeters (3 shared papers)Sid Suggs (2 shared papers)David Chang (2 shared papers)Michael Wolf (2 shared papers)
- Journals
- Molecular Cancer Therapeutics (15 papers)Cancer Research (10 papers)Journal of Clinical Oncology (6 papers)International Journal of Oncology (6 papers)Cancer and Metastasis Reviews (5 papers)
- Partner nations
- United StatesAustraliaGermany
In The Last Decade
Robert Radinsky
130 papers receiving 10.5k citations
Robert Radinsky's Hit Papers
Peers
Comparison fields: 5 of 118
- Oncology 5.8k
- Cancer Research 1.9k
- Hepatology 808
- Immunology and Allergy 450
- Biotechnology 650
Countries citing papers authored by Robert Radinsky
This map shows the geographic impact of Robert Radinsky's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Radinsky with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Radinsky more than expected).
Fields of papers citing papers by Robert Radinsky
This network shows the impact of papers produced by Robert Radinsky. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Radinsky. The network helps show where Robert Radinsky may publish in the future.
Co-authors
The 25 scholars most cited alongside Robert Radinsky, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 133 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Hit paper breakdown → | 2008 | 2515 |
| 2 | Wild-Type Human p53 and a Temperature-Sensitive Mutant Induce Fas/APO-1 Expression Hit paper breakdown → | 1995 | 635 |
| 3 | Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Hit paper breakdown → | 1999 | 514 |
| 4 | Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. | 2000 | 445 |
| 5 | Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. | 2000 | 376 |
| 6 | 1998 | 363 | |
| 7 | Expression of interleukin 8 correlates with the metastatic potential of human melanoma cells in nude mice. | 1994 | 328 |
| 8 | Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. | 2000 | 324 |
| 9 | Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. | 1995 | 284 |
| 10 | Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. | 1994 | 244 |
| 11 | 2006 | 211 | |
| 12 | Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. | 2000 | 204 |
| 13 | 2008 | 202 | |
| 14 | Interleukin 8 expression regulates tumorigenicity and metastasis in human bladder cancer. | 2000 | 186 |
| 15 | 2002 | 151 | |
| 16 | 1994 | 145 | |
| 17 | 2008 | 136 | |
| 18 | 2002 | 129 | |
| 19 | Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. | 2002 | 128 |
| 20 | 2015 | 122 |
About Robert Radinsky
Robert Radinsky is a scholar working on Oncology, Molecular Biology, Cancer Research, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 133 papers that have together received 10.9k indexed citations. Recurring topics across this work include Cancer, Hypoxia, and Metabolism (30 papers), Cancer Cells and Metastasis (16 papers), Liver physiology and pathology (15 papers), HER2/EGFR in Cancer Research (15 papers), Colorectal Cancer Treatments and Studies (15 papers), Angiogenesis and VEGF in Cancer (14 papers), Growth Hormone and Insulin-like Growth Factors (13 papers) and Cancer-related Molecular Pathways (12 papers). The work is most often cited by research in Oncology (5.8k citations), Cancer Research (1.9k citations), Hepatology (808 citations), Immunology and Allergy (450 citations) and Biotechnology (650 citations). Robert Radinsky has collaborated with scholars based in United States, Australia and Germany. Frequent co-authors include Daniel J. Freeman, Todd Juan, Rafael G. Amado, Eric Van Cutsem, Marc Peeters, Sid Suggs, David Chang, Michael Wolf, Salvatore Siena and Robert Sikorski. Their work appears in journals such as Molecular Cancer Therapeutics, Cancer Research, Journal of Clinical Oncology, International Journal of Oncology and Cancer and Metastasis Reviews.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.